Top 3 Canadian Cannabis Stocks to Watch in February 2026The Canadian cannabis sector continues to evolve in early 2026. Although volatility remains, investor interest is returning. Regulatory discussions in the United States are once again gaining momentum. Because of that, Canadian operators with U.S. exposure are drawing attention. Many investors are watching companies positioned for cross-border expansion.Canada remains a mature recreational market. However, growth there has slowed compared to earlier ye ...

Tilray Brands (NASDAQ: TLRY) is focused on expanding its reach. The marijuana company has now branched out to include CBD products and alcohol, and has started to call itself "a global lifestyle and consumer packaged goods company." It's not a bad idea, given the headwinds in the marijuana space, but there are material risks to consider here. The marijuana market hasn't panned out as hoped The first big problem with Tilray Brands isn't actually specific to the company. It is a problem that the entire mar ...

Wall Street can be very unforgiving. Unfortunately, a stock doesn't remember prices it once traded at -- and prices can keep rising or falling. Investors have seen this firsthand with Tilray Brands (NASDAQ: TLRY), a once-promising cannabis stock. Its shares have declined 16% over the past year. Even worse, the stock is down by 74% over the past three years and 97% over the past five years. Why has Tilray stock struggled, and is it time that investors dump their shares? Where to invest $1,000 right now? Ou ...

Core Viewpoint - Tilray Brands is struggling to achieve profitability despite its diverse product offerings in the beverage, cannabis, and wellness industries, with significant competition and ongoing losses impacting its financial performance [1][4]. Group 1: Financial Performance - Tilray Brands' stock price has decreased by 99% from its all-time high, reflecting investor fatigue over the company's inability to generate profits [4]. - The company has been expanding aggressively into other areas, particularly alcohol, but this strategy has not yet resulted in positive earnings [4]. Group 2: Revenue Growth and Strategy - Tilray is focusing on revenue growth through aggressive brand acquisitions since 2021, which has led to increased revenue and potential synergies [5]. - However, the rising share count due to stock sales for cash or acquisitions is diluting existing shareholders and complicating profit generation [6]. Group 3: Investment Risks - The ongoing losses and aggressive acquisition strategy present high risks for investors, with the company having to take write-downs across all divisions [7]. - Investors are advised to be cautious and may benefit from observing the company's performance before committing capital [7].

In the latest trading session, Tilray Brands, Inc. (TLRY) closed at $7.75, marking a -1.77% move from the previous day. This change lagged the S&P 500's daily gain of 0.69%. Elsewhere, the Dow saw an upswing of 0.47%, while the tech-heavy Nasdaq appreciated by 0.9%. Heading into today, shares of the company had lost 13.58% over the past month, lagging the Medical sector's gain of 0.77% and the S&P 500's loss of 1%.The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. T ...

Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

This story was originally published on Food Dive. To receive daily news and insights, subscribe to our free daily Food Dive newsletter. Cannabis and craft beer producer Tilray Brands has landed a licensing agreement with Carlsberg Group for the production, marketing and selling of the Danish brewing giant's beer portfolio in the U.S. The five-year agreement is set to begin in 2027, with an automatic renewal option for another five years subject to performance criteria, according to a press release Wednesd ...

Tilray Brands has struck a deal to brew for Carlsberg in the US. A statement from the US-based cannabis and drinks producer confirmed it will brew, sell and distribute Carlsberg brands including Carlsberg and 1664 across the country from January. The Danish brewing giant presently exports its beers to the US. According to the statement, the agreement lasts five years, and includes an automatic renewal for another five "subject to performance criteria". Tilray chairman and CEO Irwin Simon said: "This p ...

Core Viewpoint - Tilray Brands, Inc. has entered into an exclusive licensing agreement with the Carlsberg Group to produce, market, and distribute Carlsberg-branded beers in the U.S. starting January 1, 2027, enhancing Tilray's position in the beverage market [1][2][3]. Group 1: Agreement Details - The licensing agreement grants Tilray a multi-year license to produce and distribute Carlsberg®, Carlsberg Elephant®, 1664®, and Kronenbourg 1664 Blanc® beers in the U.S. with an initial five-year term and an automatic renewal for an additional five years based on performance [2]. - The agreement is set to commence on January 1, 2027, and is expected to deliver immediate scale and revenue growth as the Carlsberg portfolio is anticipated to drive volume growth and expand shelf presence [8]. Group 2: Strategic Implications - Tilray will utilize its brewing facilities and commercial expertise to enhance Carlsberg's market share in the U.S., which is the world's second-largest beer market [3]. - The partnership is expected to strengthen Tilray's beverage platform by combining Carlsberg's global brand recognition with Tilray's operational scale and quality standards [4]. Group 3: Operational Enhancements - The agreement will leverage Tilray's operational footprint across brewing, sourcing, packaging, and logistics to drive cost efficiencies and strengthen supply chain resilience [6]. - The collaboration is projected to enhance Tilray's product mix and distributor positioning, thereby reinforcing its category leadership in the U.S. beverage market [8]. Group 4: Company Background - Tilray Beverages is a division of Tilray Brands, which has a diverse portfolio of craft beers, spirits, and non-alcoholic beverages, focusing on expanding premium and mainstream offerings across the U.S. [7]. - Carlsberg Group, founded in 1847, is one of the world's leading brewing companies with a presence in over 150 markets and employs more than 37,000 people globally [6].

Tilray Brands, Inc. (NASDAQ:TLRY) is among the 7 Best Cannabis Stocks to Invest In Now. Canaccord Analyst Initiates Coverage on Tilray Brands, Inc. (TLRY) Tilray Brands, Inc. (NASDAQ:TLRY) is among the Best Marijuana Stocks.  Canaccord analyst Kenric Tyghe began covering Tilray Brands, Inc. (NASDAQ:TLRY) on January 27, 2026, according to TheFly, with a C$13 price target and a Hold rating. According to the company, despite legislative obstacles and structural inefficiencies, the Canadian cannabis industr ...